{"entity":{"id":"kathleen-moore","kind":"person","name":"Kathleen N. Moore","aka":[],"tldr":"Led SOLO-1 and MIRASOL, which gave ovarian cancer a maintenance PARP inhibitor and its first ADC with a survival benefit.","summary":"Kathleen Moore was principal investigator of SOLO-1, which showed two years of maintenance olaparib after first-line chemotherapy dramatically extends progression-free survival in BRCA-mutant ovarian cancer and later showed a survival benefit, and of MIRASOL, which showed mirvetuximab soravtansine improves survival in platinum-resistant folate receptor alpha-high disease, the first ADC to do so in ovarian cancer. She is associate director of the GOG Partners programme and leads early-phase gynaecological trials.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Moore%20KN%5BAuthor%5D%20ovarian%20olaparib%20OR%20mirvetuximab"}],"tags":["ovarian","parp","adc","trialist"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":["parp-inhibitor","adc"],"targets":["parp","brca","folr1"],"drugs":["olaparib","mirvetuximab-soravtansine"],"companies":["gog-foundation"],"institutions":["stephenson-oklahoma"],"pathways":[],"terms":[],"trials":["solo-1","mirasol"],"people":[],"bottlenecks":[],"keyPapers":["paper-solo-1-nejm-2018"],"journals":[],"dependsOn":[],"notes":[],"role":"Associate Director of Clinical Research, Stephenson Cancer Center, University of Oklahoma","institutionId":"stephenson-oklahoma","specialisms":["Ovarian cancer","PARP inhibitors","Antibody-drug conjugates","Early drug development"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Moore%20KN%5BAuthor%5D%20ovarian%20olaparib%20OR%20mirvetuximab"}],"papers":[{"title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer (SOLO-1)","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1810858"},{"title":"Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer (MIRASOL)","journal":"NEJM","year":2023,"doi":"10.1056/NEJMoa2309169"}]},"route":"/people/kathleen-moore/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"}],"target":[{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/"},{"id":"folr1","kind":"target","name":"Folate receptor alpha","route":"/targets/folr1/"},{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"mirvetuximab-soravtansine","kind":"drug","name":"Mirvetuximab soravtansine","route":"/drugs/mirvetuximab-soravtansine/"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"}],"company":[{"id":"gog-foundation","kind":"company","name":"GOG Foundation","route":"/companies/gog-foundation/"}],"institution":[{"id":"stephenson-oklahoma","kind":"institution","name":"Stephenson Cancer Center, OU Health","route":"/institutions/stephenson-oklahoma/"}],"trial":[{"id":"mirasol","kind":"trial","name":"MIRASOL / GOG-3045","route":"/trials/mirasol/"},{"id":"solo-1","kind":"trial","name":"SOLO-1","route":"/trials/solo-1/"}],"paper":[{"id":"paper-solo-1-nejm-2018","kind":"paper","name":"SOLO-1: two years of olaparib maintenance after first-line chemotherapy for BRCA-mutated ovarian cancer","route":"/key-papers/paper-solo-1-nejm-2018/"}]}}